NCT01723475View on ClinicalTrials.gov

First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

November 2, 2012

Primary Completion Date

July 18, 2018

Study Completion Date

September 26, 2018

Conditions
Prostatic Neoplasms
Interventions
BIOLOGICAL

BAY2010112

Subcutaneous (s.c.) administration once daily. Starting dose will be 0.5 µg ; dose will be escalated dependent on any dose limiting toxicities

BIOLOGICAL

BAY2010112

Continuous intravenous infusion (c.i.v.) administration. Starting dose will be 5 µg ; dose will be escalated dependent on any dose limiting toxicities.

Trial Locations (5)

1100

Vienna

4010

Linz

12200

Berlin

69120

Heidelberg

97080

Würzburg

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01723475 - First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter